Nature Communications (Mar 2019)
TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone
- Hiroaki Saito,
- Andreas Gasser,
- Simona Bolamperti,
- Miki Maeda,
- Levi Matthies,
- Katharina Jähn,
- Courtney L. Long,
- Hartmut Schlüter,
- Marcel Kwiatkowski,
- Vaibhav Saini,
- Paola Divieti Pajevic,
- Teresita Bellido,
- Andre J. van Wijnen,
- Khalid S. Mohammad,
- Theresa A. Guise,
- Hanna Taipaleenmäki,
- Eric Hesse
Affiliations
- Hiroaki Saito
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Andreas Gasser
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Simona Bolamperti
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Miki Maeda
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Levi Matthies
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Katharina Jähn
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Courtney L. Long
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Hartmut Schlüter
- Mass Spectrometric Proteomics Laboratory, Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
- Marcel Kwiatkowski
- Mass Spectrometric Proteomics Laboratory, Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
- Vaibhav Saini
- Endocrine Unit, Massachusetts General Hospital
- Paola Divieti Pajevic
- Endocrine Unit, Massachusetts General Hospital
- Teresita Bellido
- Department of Anatomy and Cell Biology, Indiana University School of Medicine
- Andre J. van Wijnen
- Department of Orthopedic Surgery, Mayo Clinic
- Khalid S. Mohammad
- Division of Endocrinology, Department of Medicine, Indiana School of Medicine
- Theresa A. Guise
- Division of Endocrinology, Department of Medicine, Indiana School of Medicine
- Hanna Taipaleenmäki
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- Eric Hesse
- Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf
- DOI
- https://doi.org/10.1038/s41467-019-08778-x
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Parathyroid hormone (PTH) is used to treat osteoporosis, but its therapeutic mechanism remains unclear. Here, the authors show that Tgif1 is a PTH target gene, and that its deletion impairs the function of osteoblasts and PTH-induced bone formation in mice.
